ESSA Ebit Per Revenue from 2010 to 2024
| EPIX Stock | USD 1.61 0.02 1.23% |
Ebit Per Revenue | First Reported 2010-12-31 | Previous Quarter -81.5 K | Current Value -85.5 K | Quarterly Volatility 2.6 K |
Check ESSA Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ESSA Pharma's main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 0.0 or Selling General Administrative of 8.2 M, as well as many indicators such as Price To Sales Ratio of 272.8 K, Dividend Yield of 0.0 or PTB Ratio of 49.54. ESSA financial statements analysis is a perfect complement when working with ESSA Pharma Valuation or Volatility modules.
ESSA | Ebit Per Revenue |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.